Spectre
Payments companies reported to CMS as associated with Spectre. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Spectre, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Spectre
These are the largest totals companies reported as associated with Spectre. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Zia Khan | Las Vegas, NV | Cardiovascular Disease | $150.00 |
| Saif Al-Adwan | Pittsburgh, PA | Interventional Cardiology | $137.76 |
| Fouad Jabbour | Greensburg, PA | Interventional Cardiology | $137.75 |
| Dmitri Samoilov | Virginia Beach, VA | Diagnostic Radiology | $80.11 |
| Jun Chung | Suffolk, VA | Interventional Cardiology | $80.10 |
| Ravi Sharma | Louisville, KY | Interventional Cardiology | $74.28 |
| Amir Piracha | Louisville, KY | Cardiovascular Disease | $67.41 |
| Naresh Solankhi | Louisville, KY | Interventional Cardiology | $59.50 |
| Ibrahim Fahsah | Louisville, KY | Interventional Cardiology | $53.97 |
| Michael Bashline | Pittsburgh, PA | Cardiovascular Disease | $23.29 |
Prescribed Spectre?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.